Why the study?
Bleeding remains a risk with all forms of anticoagulation in atrial fibrillation and has infrequently been reported in the form of hemopericardium.
This case highlights the rare but severe bleeding risk of spontaneous hemopericardium associated with oral anticoagulant therapy in patients with atrial fibrillation.
Rare hemopericardium risk on warfarin in elderly AF warrants vigilance; single case leaves incidence and prevention open.
Anticoagulation therapy is of paramount importance in atrial fibrillation (AF) because of the substantial risk for stroke associated with high morbidity and mortality. The current therapeutic options include vitamin K antagonists and novel oral anticoagulant agents. Despite meticulous therapy selection, the risk for bleeding remains with all forms of anticoagulation and has infrequently been reported in the form of hemopericardium. We highlight a patient case of an 84-year-old man with a history of permanent atrial fibrillation on warfarin who presented with shortness of breath and was found to have a massive hemopericardium.
No takes yet. Share an insight, caveat, or question.
Patil et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: